DIA Biosimilars 2013

Heptares Therapeutics

Heptares grants Shire worldwide NDC license

Wednesday, July 3, 2013 10:00 AM

Shire has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares Therapeutics, currently in preclinical development. Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor is a validated mechanism in the treatment of CNS disorders.

More... »

Cenduit: Now with Patient Reminders

MorphoSys, Heptares to develop antibody therapeutics targeting GPCRs

Wednesday, February 13, 2013 10:03 AM

MorphoSys, a biotechnology company focused on fully human antibodies, and Heptares Therapeutics, a developer of new medicines targeting G protein-coupled receptors (GPCRs), have signed an agreement to discover novel antibody therapeutics targeting GPCRs—membrane proteins involved in a broad range of biological processes and diseases.

More... »

CRF Health – eCOA Forum

Shire to license CNS disorder drug worldwide

Wednesday, March 21, 2012 10:36 AM

Heptares Therapeutics, a U.K.-based drug discovery company, has granted Shire Pharmaceuticals, the global specialty biopharmaceutical company, exclusive worldwide license of novel adenosine A2A antagonist for central nervous system disorders, currently in preclinical development.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs